{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:05:45Z","timestamp":1791947145485,"version":"4.3.4"},"reference-count":254,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515011713"],"award-info":[{"award-number":["2024A1515011713"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2026A1515010357"],"award-info":[{"award-number":["2026A1515010357"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program Key Projects","doi-asserted-by":"publisher","award":["202102070001"],"award-info":[{"award-number":["202102070001"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program Key Projects","doi-asserted-by":"publisher","award":["2024A04J9919"],"award-info":[{"award-number":["2024A04J9919"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program Key Projects","doi-asserted-by":"publisher","award":["2025A03J3163"],"award-info":[{"award-number":["2025A03J3163"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012692","name":"K. C. Wong Education Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018608","name":"High-end Foreign Experts Recruitment Plan of China","doi-asserted-by":"publisher","award":["H20240799"],"award-info":[{"award-number":["H20240799"]}],"id":[{"id":"10.13039\/501100018608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["21623407"],"award-info":[{"award-number":["21623407"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473879"],"award-info":[{"award-number":["82473879"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273893"],"award-info":[{"award-number":["82273893"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373829"],"award-info":[{"award-number":["82373829"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["W2531016"],"award-info":[{"award-number":["W2531016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["JCYJ20250604183522028"],"award-info":[{"award-number":["JCYJ20250604183522028"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.apsb.2026.05.032","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:32:04Z","timestamp":1781224324000},"page":"5509-5539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Emerging organoids and organoids-on-chip platforms for translational development of antibody\u2012drug conjugates and next-generation bioconjugates"],"prefix":"10.1016","volume":"16","author":[{"given":"Zhuoliang","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0664-3182","authenticated-orcid":false,"given":"Yuheng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxian","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanghong","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Vankelecom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0357-0124","authenticated-orcid":false,"given":"Michela","family":"Deleidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenzhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5612-4331","authenticated-orcid":false,"given":"Zhengjin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9470-8143","authenticated-orcid":false,"given":"Sumin","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2026.05.032_bib1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody\u2013drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.apsb.2026.05.032_bib2","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody\u2013drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2026.05.032_bib3","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.apsb.2026.05.032_bib4","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2229101","article-title":"Exploration of the antibody\u2013drug conjugate clinical landscape","volume":"15","author":"Maecker","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.apsb.2026.05.032_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41587-025-02987-0","article-title":"Now with oligos: antibody\u2013oligonucleotide conjugates are the new drug modality to watch","volume":"44","author":"Sheridan","year":"2026","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.05.032_bib6","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/j.semnuclmed.2025.08.002","article-title":"Radiolabeled antibody\u2013drug conjugates in the treatment of solid tumors","volume":"55","author":"Lawal","year":"2025","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.apsb.2026.05.032_bib7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41587-025-02772-z","article-title":"Antibody\u2013bottlebrush prodrug conjugates for targeted cancer therapy","volume":"44","author":"Liu","year":"2026","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.05.032_bib8","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2026.2614669","article-title":"Antibodies to watch in 2026","volume":"18","author":"Crescioli","year":"2026","journal-title":"mAbs"},{"key":"10.1016\/j.apsb.2026.05.032_bib9","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody\u2013drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.05.032_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/026119291404200306","article-title":"An analysis of the use of animal models in predicting human toxicology and drug safety","volume":"42","author":"Bailey","year":"2014","journal-title":"Altern Lab Anim"},{"key":"10.1016\/j.apsb.2026.05.032_bib11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.apsb.2026.05.032_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev.pathol.3.121806.154244","article-title":"Mouse models of cancer","volume":"6","author":"Cheon","year":"2011","journal-title":"Annu Rev Pathol:Mech Dis"},{"key":"10.1016\/j.apsb.2026.05.032_bib13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bjc.6600052","article-title":"Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: involvement of microvascular hot spots induced in hypoxic foci by interleukin 8","volume":"86","author":"Rofstad","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2026.05.032_bib14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","article-title":"Organoids in cancer research","volume":"18","author":"Drost","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2026.05.032_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1083\/jcb.137.1.231","article-title":"Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies","volume":"137","author":"Weaver","year":"1997","journal-title":"J Cell Biol"},{"key":"10.1016\/j.apsb.2026.05.032_bib16","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1126\/science.1064829","article-title":"Taking cell-matrix adhesions to the third dimension","volume":"294","author":"Cukierman","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.05.032_bib17","first-page":"113","article-title":"Growth of multicell spheroids in tissue culture as a model of nodular carcinomas","volume":"46","author":"Sutherland","year":"1971","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.apsb.2026.05.032_bib18","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","article-title":"Organoid profiling identifies common responders to chemotherapy in pancreatic cancer","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2026.05.032_bib19","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.05.032_bib20","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","article-title":"An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity","volume":"25","author":"Kopper","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.05.032_bib21","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid modeling of the tumor immune microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.05.032_bib22","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41467-024-46167-1","article-title":"Delivery of a BET protein degrader via a CEACAM6-targeted antibody\u2013drug conjugate inhibits tumour growth in pancreatic cancer models","volume":"15","author":"Nakazawa","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.05.032_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41421-020-0171-1","article-title":"A PROTAC peptide induces durable \u03b2-catenin degradation and suppresses wnt-dependent intestinal cancer","volume":"6","author":"Liao","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.apsb.2026.05.032_bib24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A living biobank of breast cancer organoids captures disease heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.05.032_bib25","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.stem.2016.04.003","article-title":"A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis","volume":"18","author":"Fujii","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.apsb.2026.05.032_bib26","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody\u2013drug conjugates for cancer therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2026.05.032_bib27","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2026.05.032_bib28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.apsb.2026.05.032_bib29","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody\u2013drug conjugates: an emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew Chem, Int Ed"},{"key":"10.1016\/j.apsb.2026.05.032_bib30","doi-asserted-by":"crossref","first-page":"5632","DOI":"10.1016\/j.apsb.2025.08.016","article-title":"Next-generation clinically relevant antibody detection: unlocking electrochemical biosensors for critical disease management","volume":"15","author":"Zhao","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.05.032_bib31","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1016\/j.apsb.2024.06.007","article-title":"Multiepitope recognition technology promotes the in-depth analysis of antibody\u2012drug conjugates","volume":"14","author":"Lei","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.05.032_bib32","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.3390\/cancers15153886","article-title":"Antibody\u2012drug conjugates: a review of approved drugs and their clinical level of evidence","volume":"15","author":"Gogia","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.apsb.2026.05.032_bib33","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.4155\/bio.13.72","article-title":"PK assays for antibody\u2013drug conjugates: case study with ado-trastuzumab emtansine","volume":"5","author":"Dere","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.apsb.2026.05.032_bib34","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of antibody\u2013drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2026.05.032_bib35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/B978-0-12-396962-0.00010-0","article-title":"Practical theoretic guidance for the design of tumor-targeting agents","volume":"503","author":"Wittrup","year":"2012","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.apsb.2026.05.032_bib36","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of resistance to antibody\u2013drug conjugates","volume":"15","author":"Loganzo","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.apsb.2026.05.032_bib37","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1158\/1078-0432.CCR-09-0636","article-title":"Resistance to trastuzumab in breast cancer","volume":"15","author":"Pohlmann","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib38","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-17-3671","article-title":"Resistance to antibody\u2012drug conjugates","volume":"78","author":"Garc\u00eda-Alonso","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54849-w","article-title":"Improving the odds of drug development success through human genomics: modelling study","volume":"9","author":"Hingorani","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.05.032_bib40","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review","volume":"11","author":"Fogel","year":"2018","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.apsb.2026.05.032_bib41","first-page":"745","article-title":"Advances in preclinical evaluation of experimental antibody\u2012drug conjugates","volume":"4","author":"Lyons","year":"2021","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.apsb.2026.05.032_bib42","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-22-2981","article-title":"Preclinical efficacy of the antibody\u2012drug conjugate CLDN6-23-ADC for the treatment of CLDN6-positive solid tumors","volume":"29","author":"McDermott","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2024.126232","article-title":"Titer and charge-based heterogeneity multiattribute monitoring of mAbs in cell culture harvest using 2D ProA CEX MS","volume":"276","author":"Sarin","year":"2024","journal-title":"Talanta"},{"key":"10.1016\/j.apsb.2026.05.032_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody\u2012drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2026.05.032_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12929-024-00994-y","article-title":"Scaffold-based 3D cell culture models in cancer research","volume":"31","author":"Abuwatfa","year":"2024","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.apsb.2026.05.032_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202302377","article-title":"A HER2-targeted antibody\u2012drug conjugate, RC48-ADC, exerted promising antitumor efficacy and safety with intravesical instillation in preclinical models of bladder cancer","volume":"10","author":"Hong","year":"2023","journal-title":"Adv Sci"},{"key":"10.1016\/j.apsb.2026.05.032_bib47","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1158\/1535-7163.MCT-23-0198","article-title":"AMT-562, a novel HER3-targeting antibody\u2012drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors","volume":"22","author":"Weng","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.apsb.2026.05.032_bib48","first-page":"910","article-title":"2D and 3D cell cultures\u2012a comparison of different types of cancer cell cultures","volume":"14","author":"Kapalczynska","year":"2018","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.apsb.2026.05.032_bib49","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/267531a0","article-title":"Relationship between cell shape and type of collagen synthesised as chondrocytes lose their cartilage phenotype in culture","volume":"267","author":"Von Der Mark","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.05.032_bib50","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1242\/jcs.017640","article-title":"ADF\/cofilin family proteins control formation of oriented actin-filament bundles in the cell body to trigger fibroblast polarization","volume":"120","author":"Mseka","year":"2007","journal-title":"J Cell Sci"},{"key":"10.1016\/j.apsb.2026.05.032_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13058-015-0523-1","article-title":"Patient-derived xenograft models of breast cancer and their predictive power","volume":"17","author":"Whittle","year":"2015","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib52","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMra1806175","article-title":"Organoids\u2012preclinical models of human disease","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.05.032_bib53","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1158\/1535-7163.MCT-14-0040-T","article-title":"Preclinical profile of the HER2-targeting ADC SYD983\/SYD985: introduction of a new duocarmycin-based linker-drug platform","volume":"13","author":"Dokter","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.apsb.2026.05.032_bib54","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1158\/1078-0432.CCR-17-0219","article-title":"Fractionated dosing improves preclinical therapeutic index of pyrrolobenzodiazepine-containing antibody drug conjugates","volume":"23","author":"Hinrichs","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib55","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41467-023-44533-z","article-title":"The HER2-directed antibody\u2012drug conjugate DHES0815A in advanced and\/or metastatic breast cancer: preclinical characterization and phase 1 trial results","volume":"15","author":"Lewis","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.05.032_bib56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12935-022-02454-9","article-title":"Patient-derived xenograft models in hepatopancreatobiliary cancer","volume":"22","author":"Pan","year":"2022","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.apsb.2026.05.032_bib57","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1208\/s12248-015-9738-4","article-title":"Antibody drug conjugates: preclinical considerations","volume":"17","author":"Bornstein","year":"2015","journal-title":"AAPS J"},{"key":"10.1016\/j.apsb.2026.05.032_bib58","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s43018-022-00337-6","article-title":"A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology","volume":"3","author":"Guillen","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.apsb.2026.05.032_bib59","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-019-0829-z","article-title":"Applications of patient-derived tumor xenograft models and tumor organoids","volume":"13","author":"Yoshida","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2026.05.032_bib60","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nm.4472","article-title":"Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF\/MEK inhibitors","volume":"24","author":"Boshuizen","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.05.032_bib61","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3390\/cancers13040874","article-title":"Organoid and spheroid tumor models: techniques and applications","volume":"13","author":"Gunti","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.apsb.2026.05.032_bib62","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/1087057104265040","article-title":"The use of 3-D cultures for high-throughput screening: the multicellular spheroid model","volume":"9","author":"Kunz-Schughart","year":"2004","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.apsb.2026.05.032_bib63","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12967-016-0855-3","article-title":"Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids","volume":"14","author":"Halfter","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.apsb.2026.05.032_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.116886","article-title":"Bronchioalveolar organoids: a preclinical tool to screen toxicity associated with antibody\u2012drug conjugates","volume":"485","author":"McCray","year":"2024","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.apsb.2026.05.032_bib65","doi-asserted-by":"crossref","first-page":"7131","DOI":"10.3390\/ijms25137131","article-title":"Epidermal growth factor receptor targeting in colorectal carcinoma: antibodies and patient-derived organoids as a smart model to study therapy resistance","volume":"25","author":"Tardito","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.05.032_bib66","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","article-title":"Prospective derivation of a living organoid biobank of colorectal cancer patients","volume":"161","author":"van de Wetering","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.05.032_bib67","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41592-025-02769-1","article-title":"From 2D to 3D and beyond: the evolution and impact of in vitro tumor models in cancer research","volume":"22","author":"Rauner","year":"2025","journal-title":"Nat Methods"},{"key":"10.1016\/j.apsb.2026.05.032_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115586","article-title":"Next generation organoid engineering to replace animals in cancer drug testing","volume":"213","author":"Hockney","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2026.05.032_bib69","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41580-020-0259-3","article-title":"Human organoids: model systems for human biology and medicine","volume":"21","author":"Kim","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.apsb.2026.05.032_bib70","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1038\/s41596-020-0379-4","article-title":"Establishment of patient-derived cancer organoids for drug-screening applications","volume":"15","author":"Driehuis","year":"2020","journal-title":"Nat Protoc"},{"key":"10.1016\/j.apsb.2026.05.032_bib71","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1126\/science.aaw6985","article-title":"Cancer modeling meets human organoid technology","volume":"364","author":"Tuveson","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.05.032_bib72","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1073\/pnas.1803595116","article-title":"Mouse and human urothelial cancer organoids: a tool for bladder cancer research","volume":"116","author":"Mullenders","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.05.032_bib73","doi-asserted-by":"crossref","DOI":"10.1126\/science.1247125","article-title":"Organogenesis in a dish: modeling development and disease using organoid technologies","volume":"345","author":"Lancaster","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.05.032_bib74","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","article-title":"Modeling development and disease with organoids","volume":"165","author":"Clevers","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.05.032_bib75","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature07935","article-title":"Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche","volume":"459","author":"Sato","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.05.032_bib76","doi-asserted-by":"crossref","DOI":"10.2144\/fsoa-2019-0065","article-title":"Autologous induced pluripotent stem cell-derived four-organ-chip","volume":"5","author":"Ramme","year":"2019","journal-title":"Future Sci OA"},{"key":"10.1016\/j.apsb.2026.05.032_bib77","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.aau5729","article-title":"Assembling human brain organoids","volume":"363","author":"Pasca","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.05.032_bib78","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.cell.2020.11.017","article-title":"Generation of functional human 3D cortico-motor assembloids","volume":"183","author":"Andersen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.05.032_bib79","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/s41587-020-00763-w","article-title":"Generation of human striatal organoids and cortico-striatal assembloids from human pluripotent stem cells","volume":"38","author":"Miura","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.05.032_bib80","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1242\/dev.118570","article-title":"Modeling mouse and human development using organoid cultures","volume":"142","author":"Huch","year":"2015","journal-title":"Development"},{"key":"10.1016\/j.apsb.2026.05.032_bib81","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41416-024-02665-z","article-title":"Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models","volume":"130","author":"Arshad","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2026.05.032_bib82","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature12271","article-title":"Vascularized and functional human liver from an iPSC-derived organ bud transplant","volume":"499","author":"Takebe","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.05.032_bib83","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41592-019-0586-5","article-title":"Engineering of human brain organoids with a functional vascular-like system","volume":"16","author":"Cakir","year":"2019","journal-title":"Nat Methods"},{"key":"10.1016\/j.apsb.2026.05.032_bib84","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/WNR.0000000000001014","article-title":"Generation of human vascularized brain organoids","volume":"29","author":"Pham","year":"2018","journal-title":"Neuroreport"},{"key":"10.1016\/j.apsb.2026.05.032_bib85","doi-asserted-by":"crossref","DOI":"10.1126\/science.adu9375","article-title":"Gastruloids enable modeling of the earliest stages of human cardiac and hepatic vascularization","volume":"388","author":"Abilez","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.05.032_bib86","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41568-024-00706-6","article-title":"Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment","volume":"24","author":"Polak","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2026.05.032_bib87","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41576-018-0051-9","article-title":"Progress and potential in organoid research","volume":"19","author":"Rossi","year":"2018","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.apsb.2026.05.032_bib88","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41577-019-0248-y","article-title":"Organoids in immunological research","volume":"20","author":"Bar-Ephraim","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2026.05.032_bib89","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13073-018-0584-8","article-title":"Advanced model systems and tools for basic and translational human immunology","volume":"10","author":"Wagar","year":"2018","journal-title":"Genome Med"},{"key":"10.1016\/j.apsb.2026.05.032_bib90","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-022-01558-x","article-title":"In vivo development of immune tissue in human intestinal organoids transplanted into humanized mice","volume":"41","author":"Bouffi","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.05.032_bib91","first-page":"164","article-title":"Engineering human immune organoids for translational immunology","volume":"44","author":"Suhito","year":"2025","journal-title":"Bioact Mater"},{"key":"10.1016\/j.apsb.2026.05.032_bib92","first-page":"272","article-title":"Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing","volume":"33","author":"Marx","year":"2016","journal-title":"ALTEX"},{"key":"10.1016\/j.apsb.2026.05.032_bib93","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41573-020-0079-3","article-title":"Organs-on-chips: into the next decade","volume":"20","author":"Low","year":"2021","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.apsb.2026.05.032_bib94","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/d41586-025-02569-9","article-title":"Organs on chips could make biomedical research more equitable","volume":"644","author":"Del Valle","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.05.032_bib95","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1126\/science.aaw7894","article-title":"Organoids-on-a-chip","volume":"364","author":"Park","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.05.032_bib96","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.stem.2015.12.005","article-title":"Engineering stem cell organoids","volume":"18","author":"Yin","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.apsb.2026.05.032_bib97","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41592-019-0325-y","article-title":"Flow-enhanced vascularization and maturation of kidney organoids in vitro","volume":"16","author":"Homan","year":"2019","journal-title":"Nat Methods"},{"key":"10.1016\/j.apsb.2026.05.032_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119547","article-title":"Vascularized cancer on a chip: the effect of perfusion on growth and drug delivery of tumor spheroid","volume":"229","author":"Nashimoto","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2026.05.032_bib99","doi-asserted-by":"crossref","first-page":"766","DOI":"10.7150\/thno.95334","article-title":"Vascularized tumor on a microfluidic chip to study mechanisms promoting tumor neovascularization and vascular targeted therapies","volume":"15","author":"Skubal","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2026.05.032_bib100","article-title":"A vascularized tumors-on-a-chip model for studying tumor-angiogenesis interplay, heterogeneity and drug responses","volume":"32","author":"Shin","year":"2025","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.apsb.2026.05.032_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114365","article-title":"Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment","volume":"187","author":"Zhang","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"10.1016\/j.apsb.2026.05.032_bib102","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41568-018-0104-6","article-title":"Modelling cancer in microfluidic human organs-on-chips","volume":"19","author":"Sontheimer-Phelps","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2026.05.032_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1373186","article-title":"In vitro immunity: an overview of immunocompetent organ-on-chip models","volume":"15","author":"Morrison","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.05.032_bib104","series-title":"First FDA IND milestone achieved using human vascularized organoid efficacy data","year":"2025"},{"key":"10.1016\/j.apsb.2026.05.032_bib105","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1038\/s41598-018-22749-0","article-title":"Interconnected microphysiological systems for quantitative biology and pharmacology studies","volume":"8","author":"Edington","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.05.032_bib106","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41551-019-0497-x","article-title":"Robotic fluidic coupling and interrogation of multiple vascularized organ chips","volume":"4","author":"Novak","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2026.05.032_bib107","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1039\/D4LC01085J","article-title":"Exploring microfluidics-based organoid interactions through analysis of albumin secretion","volume":"25","author":"Yang","year":"2025","journal-title":"Lab Chip"},{"key":"10.1016\/j.apsb.2026.05.032_bib108","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1386","article-title":"Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics","volume":"11","author":"McAleer","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2026.05.032_bib109","first-page":"1012","article-title":"Organ-on-a-chip platforms for accelerating the evaluation of nanomedicine","volume":"6","author":"Chen","year":"2021","journal-title":"Bioact Mater"},{"key":"10.1016\/j.apsb.2026.05.032_bib110","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2413684121","article-title":"A closed-loop modular multiorgan-on-chips platform for self-sustaining and tightly controlled oxygenation","volume":"121","author":"Jiang","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.05.032_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2023.115285","article-title":"Biosensors integrated 3D organoid\/organ-on-a-chip system: a real-time biomechanical, biophysical, and biochemical monitoring and characterization","volume":"231","author":"Liu","year":"2023","journal-title":"Biosens Bioelectron"},{"key":"10.1016\/j.apsb.2026.05.032_bib112","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1021\/acssensors.2c00333","article-title":"Biosensors integration in blood\u2013brain barrier-on-a-chip: emerging platform for monitoring neurodegenerative diseases","volume":"7","author":"Mir","year":"2022","journal-title":"ACS Sens"},{"key":"10.1016\/j.apsb.2026.05.032_bib113","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202403560","article-title":"Liver-on-a-chip integrated with label-free optical biosensors for rapid and continuous monitoring of drug-induced toxicity","volume":"20","author":"Yang","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.apsb.2026.05.032_bib114","doi-asserted-by":"crossref","first-page":"38305","DOI":"10.1021\/acsnano.5c09883","article-title":"An organoid biosensing platform for personalized prognosis of bladder cancer","volume":"19","author":"Yan","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2026.05.032_bib115","series-title":"NIH Standardized Organoid Modeling (SOM) Center","year":"2025"},{"key":"10.1016\/j.apsb.2026.05.032_bib116","series-title":"The U.S. Food and Drug Administration. NIH announces end to funding for animal-only studies","year":"2025"},{"key":"10.1016\/j.apsb.2026.05.032_bib117","series-title":"Roadmap to reducing animal testing in preclinical safety studies","year":"2025"},{"key":"10.1016\/j.apsb.2026.05.032_bib118","series-title":"Exclusive: CDC to end all monkey research","year":"2025"},{"key":"10.1016\/j.apsb.2026.05.032_bib119","series-title":"FDA modernization act 2.0","year":"2022"},{"key":"10.1016\/j.apsb.2026.05.032_bib120","series-title":"FDA modernization act 3.0","year":"2025"},{"key":"10.1016\/j.apsb.2026.05.032_bib121","unstructured":"The U.S. Food and Drug Administration, Oncology pharmaceuticals: streamlined nonclinical safety studies for biologics and conjugated products, 2026. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/oncology-pharmaceuticals-streamlined-nonclinical-safety-studies-biologics-and-conjugated-products"},{"key":"10.1016\/j.apsb.2026.05.032_bib122","unstructured":"The U.S. environmental protection agency, Trump EPA takes new action to eliminate animal testing, 2026. Available from: https:\/\/www.epa.gov\/newsreleases\/trump-epa-takes-new-action-eliminate-animal-testing"},{"key":"10.1016\/j.apsb.2026.05.032_bib123","series-title":"Replacing animals in science: a strategy to support the development, validation and uptake of alternative methods (CP 1429)","author":"Government","year":"2025"},{"key":"10.1016\/j.apsb.2026.05.032_bib124","series-title":"Cosmetics supervision and administration regulation: alternative testing methods and iata integration","year":"2021"},{"key":"10.1016\/j.apsb.2026.05.032_bib125","series-title":"Human Organoid Research Ethical Guidelines","year":"2025"},{"key":"10.1016\/j.apsb.2026.05.032_bib126","unstructured":"European Commission, Roadmap towards phasing out animal testing, 2026. Available from: https:\/\/single-market-economy.ec.europa.eu\/sectors\/chemicals\/reach\/roadmap-towards-phasing-out-animal-testing_en#:\u223c:text=This%20comprehensive%20approach%20encompasses%20a%20wide%20range%20of,to%20facilitate%20the%20transition%20to%20alternative%20testing%20methods."},{"key":"10.1016\/j.apsb.2026.05.032_bib127","unstructured":"The Dutch Knowledge and Innovation Agenda Key, Organ-on-chip in the new action agendas for the national technology strategy, 2026. Available from: https:\/\/www.hdmt.technology\/2026\/01\/28\/organ-on-chip-in-the-new-action-agendas-for-the-national-technology-strategy\/"},{"key":"10.1016\/j.apsb.2026.05.032_bib128","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/s41587-025-02961-w","article-title":"2025: research in review","volume":"43","year":"2025","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.05.032_bib129","series-title":"Industry leaders announce world's first microphysiological systems Industry Association (IAMPS)","year":"2026"},{"key":"10.1016\/j.apsb.2026.05.032_bib130","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.devcel.2016.08.014","article-title":"Organoids: modeling development and the stem cell niche in a dish","volume":"38","author":"Kretzschmar","year":"2016","journal-title":"Dev Cell"},{"key":"10.1016\/j.apsb.2026.05.032_bib131","series-title":"Guidance document no. 417 on generation, reporting and use of research data for regulatory assessments","year":"2025"},{"key":"10.1016\/j.apsb.2026.05.032_bib132","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.stemcr.2021.05.012","article-title":"ISSCR guidelines for stem cell research and clinical translation: the 2021 update","volume":"16","author":"Lovell-Badge","year":"2021","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.apsb.2026.05.032_bib133","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/aor.14620","article-title":"Bioethical implications of organ-on-a-chip on modernizing drug development","volume":"47","author":"Thakar","year":"2023","journal-title":"Artif Organs"},{"key":"10.1016\/j.apsb.2026.05.032_bib134","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.stemcr.2024.04.008","article-title":"Rigor and reproducibility in human brain organoid research: where we are and where we need to go","volume":"19","author":"Sandoval","year":"2024","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.apsb.2026.05.032_bib135","doi-asserted-by":"crossref","first-page":"14375","DOI":"10.1002\/cam4.5943","article-title":"Standardization of organoid culture in cancer research","volume":"12","author":"Zhou","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.apsb.2026.05.032_bib136","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/medethics-2017-104555","article-title":"Cerebral organoids: ethical issues and consciousness assessment","volume":"44","author":"Lavazza","year":"2018","journal-title":"J Med Ethics"},{"key":"10.1016\/j.apsb.2026.05.032_bib137","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1177\/1073110519897789","article-title":"Moral limits of brain organoid research","volume":"47","author":"Koplin","year":"2019","journal-title":"J Law Med Ethics"},{"key":"10.1016\/j.apsb.2026.05.032_bib138","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/21507740.2021.1896603","article-title":"Mapping the ethical issues of brain organoid research and application","volume":"13","author":"Sawai","year":"2022","journal-title":"AJOB Neurosci"},{"key":"10.1016\/j.apsb.2026.05.032_bib139","series-title":"The emerging field of human neural organoids, transplants, and Chimeras: science, ethics, and governance","year":"2021"},{"key":"10.1016\/j.apsb.2026.05.032_bib140","first-page":"2","article-title":"Toward public bioethics?","volume":"47","author":"Kaebnick","year":"2017","journal-title":"Hastings Cent Rep"},{"key":"10.1016\/j.apsb.2026.05.032_bib141","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1126\/science.adg6228","article-title":"Advancing alternative methods to reduce animal testing","volume":"386","author":"Nelson","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.05.032_bib142","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.coph.2019.09.007","article-title":"The NIH microphysiological systems program: developing in vitro tools for safety and efficacy in drug development","volume":"48","author":"Tagle","year":"2019","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.apsb.2026.05.032_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.stemcr.2025.102686","article-title":"The ethical aspects of human organ-on-chip models: a mapping review","volume":"20","author":"Weidema","year":"2025","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.apsb.2026.05.032_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2023.115271","article-title":"Organs-on-chips technologies\u2013a guide from disease models to opportunities for drug development","volume":"231","author":"Monteduro","year":"2023","journal-title":"Biosens Bioelectron"},{"key":"10.1016\/j.apsb.2026.05.032_bib145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-15-0189","article-title":"Tumor-derived cell lines as molecular models of cancer pharmacogenomics","volume":"14","author":"Goodspeed","year":"2016","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib146","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","article-title":"Tumor evolution and drug response in patient-derived organoid models of bladder cancer","volume":"173","author":"Lee","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.05.032_bib147","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/onc.2008.394","article-title":"Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab","volume":"28","author":"Pickl","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2026.05.032_bib148","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2026.05.032_bib149","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/2159-8290.CD-22-1368","article-title":"Antibody-exatecan conjugates with a novel self-immolative moiety overcome resistance in colon and lung cancer","volume":"13","author":"Weng","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2026.05.032_bib150","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3390\/toxins3070848","article-title":"Immunotoxins and anticancer drug conjugate assemblies: te role of the linkage between components","volume":"3","author":"Dosio","year":"2011","journal-title":"Toxins"},{"key":"10.1016\/j.apsb.2026.05.032_bib151","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/s42003-024-07439-0","article-title":"Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors","volume":"7","author":"Tolosa","year":"2024","journal-title":"Commun Biol"},{"key":"10.1016\/j.apsb.2026.05.032_bib152","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1038\/s41467-019-11867-6","article-title":"Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening","volume":"10","author":"Kim","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.05.032_bib153","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/nm.3973","article-title":"Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell\u2013and patient-derived tumor organoids","volume":"21","author":"Huang","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.05.032_bib154","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1016\/j.ymthe.2022.04.013","article-title":"A highly stable human single-domain antibody\u2013drug conjugate exhibits superior penetration and treatment of solid tumors","volume":"30","author":"Wu","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.05.032_bib155","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.yexmp.2011.05.011","article-title":"Antibodies to cell surface proteins redirect intracellular trafficking pathways","volume":"91","author":"St Pierre","year":"2011","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.apsb.2026.05.032_bib156","article-title":"Development and preclinical evaluation of a novel FGFR3-targeted antibody\u2013drug conjugate in bladder cancer","volume":"20","author":"Fan","year":"2025","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.apsb.2026.05.032_bib157","article-title":"CMG901, a Claudin18.2-specific antibody\u2013drug conjugate, for the treatment of solid tumors","volume":"5","author":"Xu","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.apsb.2026.05.032_bib158","doi-asserted-by":"crossref","first-page":"7578","DOI":"10.1021\/jacs.4c16842","article-title":"Fluorogenic platform for real-time imaging of subcellular payload release in antibody\u2013drug conjugates","volume":"147","author":"Nadal-Bufi","year":"2025","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2026.05.032_bib159","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3389\/fimmu.2020.01771","article-title":"Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.05.032_bib160","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1021\/jm500766w","article-title":"Ado-trastuzumab emtansine (T-DM1): an antibody\u2013drug conjugate (ADC) for HER2-positive breast cancer","volume":"57","author":"Lambert","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.05.032_bib161","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/jcp.21832","article-title":"Advancing science and technology via 3D culture on basement membrane matrix","volume":"221","author":"Benton","year":"2009","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.apsb.2026.05.032_bib162","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/jps.22257","article-title":"A review of three-dimensional in vitro tissue models for drug discovery and transport studies","volume":"100","author":"Elliott","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2026.05.032_bib163","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00429-004-0446-6","article-title":"A comparative study of the structure of human and murine greater omentum","volume":"209","author":"Wilkosz","year":"2005","journal-title":"Anat Embryol"},{"key":"10.1016\/j.apsb.2026.05.032_bib164","first-page":"4227","article-title":"Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models","volume":"9","author":"Voskoglou-Nomikos","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib165","first-page":"205","article-title":"A novel organoid model retaining the glioma microenvironment for personalized drug screening and therapeutic evaluation","volume":"53","author":"Zheng","year":"2025","journal-title":"Bioact Mater"},{"key":"10.1016\/j.apsb.2026.05.032_bib166","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005660","article-title":"Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab","volume":"10","author":"Benelli","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.05.032_bib167","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb6282","article-title":"Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody\u2013drug conjugate","volume":"13","author":"Kong","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2026.05.032_bib168","first-page":"6944","article-title":"Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30\/anti-alkaline phosphatase monoclonal antibody","volume":"50","author":"Sahin","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib169","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody\u2013drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib170","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1039\/C7ME00093F","article-title":"Computational transport analysis of antibody\u2013drug conjugate bystander effects and payload tumoral distribution: implications for therapy","volume":"3","author":"Khera","year":"2018","journal-title":"Mol Syst Des Eng"},{"key":"10.1016\/j.apsb.2026.05.032_bib171","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/1878-0261.12650","article-title":"Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification","volume":"14","author":"Van Bockstal","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.apsb.2026.05.032_bib172","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1078-0432.CCR-23-1725","article-title":"Spatiotemporal quantification of HER2-targeting antibody\u2013drug conjugate bystander activity and enhancement of solid tumor penetration","volume":"30","author":"Wei","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib173","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113738","article-title":"Enhancing the bystander effect of antibody\u2013drug conjugate by using a novel caspase-3 cleavable peptide linker to overcome tumor heterogeneity","volume":"382","author":"Lee","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.05.032_bib174","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/1538-7445.AM2025-5195","article-title":"Development of paired PDX-PDXO preclinical models for HER2-targeting ADC efficacy evaluation","volume":"85","author":"Wang","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib175","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody\u2013drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2026.05.032_bib176","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41573-025-01182-9","article-title":"Application of new approach methodologies for nonclinical safety assessment of drug candidates","volume":"24","author":"Beilmann","year":"2025","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.apsb.2026.05.032_bib177","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody\u2013drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.apsb.2026.05.032_bib178","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2013.01.012","article-title":"A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity","volume":"268","author":"Kostadinova","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.apsb.2026.05.032_bib179","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.stem.2016.10.007","article-title":"Conversion of terminally committed hepatocytes to culturable bipotent progenitor cells with regenerative capacity","volume":"20","author":"Katsuda","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.apsb.2026.05.032_bib180","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/17425251003674356","article-title":"Three-dimensional culture of hepatocytes for prediction of drug-induced hepatotoxicity","volume":"6","author":"Meng","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.apsb.2026.05.032_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121575","article-title":"Development of human pluripotent stem cell-derived hepatic organoids as an alternative model for drug safety assessment","volume":"286","author":"Kim","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2026.05.032_bib182","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1158\/1078-0432.CCR-18-2275","article-title":"Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer","volume":"25","author":"Meric-Bernstam","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib183","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.taap.2013.09.003","article-title":"Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability","volume":"273","author":"Poon","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.apsb.2026.05.032_bib184","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10549-021-06427-w","article-title":"Trastuzumab does not bind rat or mouse ErbB2\/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics","volume":"191","author":"Phillips","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.apsb.2026.05.032_bib185","doi-asserted-by":"crossref","DOI":"10.1177\/20420986241304680","article-title":"Incidence of antibody\u2013drug conjugate-related hepatotoxicity in breast cancer: a systematic review and meta-analysis","volume":"15","author":"Yang","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.apsb.2026.05.032_bib186","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/jco.2015.33.15_suppl.2505","article-title":"A new anti-CEA-SN-38 antibody\u2013drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing chemotherapies: initial results of a phase I\/II study","volume":"33","author":"Dotan","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2026.05.032_bib187","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.apsb.2026.05.032_bib188","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202409571","article-title":"Heart-on-a-miniscope: a miniaturized solution for electrophysiological drug screening in cardiac organoids","volume":"21","author":"Tirgar","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.apsb.2026.05.032_bib189","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.biologicals.2010.03.001","article-title":"The application of ICH S6 to the preclinical safety evaluation of plasma derivative therapeutic products","volume":"38","author":"Lewis","year":"2010","journal-title":"Biologicals"},{"key":"10.1016\/j.apsb.2026.05.032_bib190","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2026.05.032_bib191","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1158\/1535-7163.MCT-21-0846","article-title":"The anti-nectin 4: a promising tumor cells target. A systematic review","volume":"21","author":"Bouleftour","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.apsb.2026.05.032_bib192","doi-asserted-by":"crossref","first-page":"E223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the nectin-4-directed antibody\u2013drug conjugate enfortumab vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.apsb.2026.05.032_bib193","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113503","article-title":"Engineering CD276\/B7-H3-targeted antibody\u2013drug conjugates with enhanced cancer-eradicating capability","volume":"42","author":"Feng","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2026.05.032_bib194","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12967-024-05133-7","article-title":"DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors","volume":"22","author":"Li","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.apsb.2026.05.032_bib195","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/17425255.2022.2162383","article-title":"Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody\u2013drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore","volume":"18","author":"Yong","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.apsb.2026.05.032_bib196","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacbts.2019.10.008","article-title":"Limitations of animal studies for predicting toxicity in clinical trials: is it time to rethink our current approach?","volume":"4","author":"Van Norman","year":"2019","journal-title":"JACC, Basic Transl Sci"},{"key":"10.1016\/j.apsb.2026.05.032_bib197","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/nbt.3392","article-title":"Nephron organoids derived from human pluripotent stem cells model kidney development and injury","volume":"33","author":"Morizane","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.05.032_bib198","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41551-023-01156-5","article-title":"Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroids","volume":"8","author":"Harter","year":"2023","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2026.05.032_bib199","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cac2.12387","article-title":"Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun"},{"key":"10.1016\/j.apsb.2026.05.032_bib200","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s41551-024-01273-9","article-title":"Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma","volume":"9","author":"Papargyriou","year":"2024","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2026.05.032_bib201","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor cells chronically treated with a trastuzumab-maytansinoid antibody\u2013drug conjugate develop varied resistance mechanisms but respond to alternate treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.apsb.2026.05.032_bib202","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1158\/1078-0432.CCR-17-0696","article-title":"Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer","volume":"23","author":"Sabbaghi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib203","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.3390\/jcm8111880","article-title":"Patient-derived head and neck cancer organoids recapitulate EGFR expression levels of respective tissues and are responsive to EGFR-targeted photodynamic therapy","volume":"8","author":"Driehuis","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.apsb.2026.05.032_bib204","doi-asserted-by":"crossref","first-page":"8406","DOI":"10.1038\/s41467-023-44162-6","article-title":"High-throughput deconvolution of 3D organoid dynamics at cellular resolution for cancer pharmacology with Cellos","volume":"14","author":"Mukashyaka","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.05.032_bib205","article-title":"SNX10 deficiency impairs sensitivity to anti-HER2 antibody\u2013drug conjugates via altering HER2 trafficking in HER2-positive breast cancer","volume":"122","author":"Chen","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.05.032_bib206","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","article-title":"Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1)","volume":"17","author":"Sung","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.apsb.2026.05.032_bib207","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1038\/s41467-022-30142-9","article-title":"Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer","volume":"13","author":"Pereira","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.05.032_bib208","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41419-025-07887-4","article-title":"Inhibition of the Caveolin-1 pathway promotes apoptosis and overcomes pan-tyrosine kinase inhibitor resistance in hepatocellular carcinoma","volume":"16","author":"Kabir","year":"2025","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2026.05.032_bib209","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: making 1+ 1> 2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.05.032_bib210","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1038\/s41467-021-23948-6","article-title":"Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action","volume":"12","author":"Kast","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.05.032_bib211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0223-5","article-title":"Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking","volume":"51","author":"Murphy","year":"2019","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.apsb.2026.05.032_bib212","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1158\/1538-7445.AM2018-3914","article-title":"ZW49, a HER2-targeted biparatopic antibody\u2013drug conjugate for the treatment of HER2-expressing cancers","volume":"78","author":"Hamblett","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib213","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41392-025-02301-z","article-title":"Targeting CD155 in lung adenocarcinoma: A5 nanobody-based therapeutics for precision treatment and enhanced drug delivery","volume":"10","author":"Noh","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2026.05.032_bib214","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the antibody\u2013drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity","volume":"77","author":"R\u00edos-Luci","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib215","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgac063","article-title":"SLC46A3 is a lysosomal proton-coupled steroid conjugate and bile acid transporter involved in transport of active catabolites of T-DM1","volume":"1","author":"Tomabechi","year":"2022","journal-title":"PNAS Nexus"},{"key":"10.1016\/j.apsb.2026.05.032_bib216","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.resinv.2025.05.012","article-title":"Mechanisms of resistance to antibody\u2013drug conjugates in cancers","volume":"63","author":"Murase","year":"2025","journal-title":"Respir Invest"},{"key":"10.1016\/j.apsb.2026.05.032_bib217","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41420-020-0246-7","article-title":"TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer","volume":"6","author":"Zhao","year":"2020","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.apsb.2026.05.032_bib218","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41467-024-44732-2","article-title":"Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson's disease model","volume":"15","author":"Morrone","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.05.032_bib219","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/d41573-021-00213-5","article-title":"Antibody-oligonucleotide conjugates enter the clinic","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.apsb.2026.05.032_bib220","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107469","article-title":"Overcoming limitations and advancing the therapeutic potential of antibody-oligonucleotide conjugates (AOCs): current status and future perspectives","volume":"209","author":"Jiao","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib221","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.117112","article-title":"Human trophoblast organoids for improved prediction of placental ABC transporter-mediated drug transport","volume":"492","author":"Huang","year":"2024","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.apsb.2026.05.032_bib222","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1535-7163.MCT-20-0222","article-title":"The role of specific ATP-binding cassette transporters in the acquired resistance to pyrrolobenzodiazepine dimer-containing antibody\u2013drug conjugates","volume":"19","author":"Corbett","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.apsb.2026.05.032_bib223","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162148","article-title":"Tumor-derived biomarkers predict efficacy of B7H3 antibody\u2013drug conjugate treatment in metastatic prostate cancer models","volume":"133","author":"Agarwal","year":"2023","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2026.05.032_bib224","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/anie.201608292","article-title":"Orthogonal cysteine protection enables homogeneous multi-drug antibody\u2013drug conjugates","volume":"56","author":"Levengood","year":"2017","journal-title":"Angew Chem, Int Ed"},{"key":"10.1016\/j.apsb.2026.05.032_bib225","first-page":"OF1","article-title":"A novel dual-payload adc platform integrating exatecan and triptolide to enhance antitumor efficacy and overcome resistance","volume":"1","author":"Ren","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.apsb.2026.05.032_bib226","article-title":"Combined therapy with DR5-targeting antibody\u2013drug conjugate and CDK inhibitors as a strategy for advanced colorectal cancer","volume":"6","author":"Zhou","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.apsb.2026.05.032_bib227","article-title":"TROP2-guided aggregation-induced emission-luminogen nanoparticles overcome sacituzumab govitecan resistance via mitochondrial oxidative stress and immunogenic cell death in triple-negative breast cancer","volume":"3","author":"Wu","year":"2025","journal-title":"Interdiscip Med"},{"key":"10.1016\/j.apsb.2026.05.032_bib228","doi-asserted-by":"crossref","first-page":"22553","DOI":"10.1021\/acsnano.3c06290","article-title":"Engineering diselenide-IR780 homodimeric nanoassemblies with enhanced photodynamic and immunotherapeutic effects for triple-negative breast cancer treatment","volume":"17","author":"Xue","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2026.05.032_bib229","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1158\/0008-5472.CAN-21-3360","article-title":"HER3 is an actionable target in advanced prostate cancer","volume":"81","author":"Gil","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib230","doi-asserted-by":"crossref","DOI":"10.1002\/imt2.70033","article-title":"Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: a multi-center real-world study","volume":"4","author":"Hu","year":"2025","journal-title":"iMeta"},{"key":"10.1016\/j.apsb.2026.05.032_bib231","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40478-016-0340-5","article-title":"From animal models to human disease: a genetic approach for personalized medicine in ALS","volume":"4","author":"Picher-Martel","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.apsb.2026.05.032_bib232","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-022-01194-6","article-title":"Applications of human organoids in the personalized treatment for digestive diseases","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2026.05.032_bib233","article-title":"A novel malignant mesothelioma organoids-T cell co-culture platform for personalized immunochemotherapy testing","volume":"15","author":"Liu","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.05.032_bib234","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/procel\/pwad038","article-title":"Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids","volume":"15","author":"Mao","year":"2023","journal-title":"Protein Cell"},{"key":"10.1016\/j.apsb.2026.05.032_bib235","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41586-019-1654-9","article-title":"Organoid single-cell genomic atlas uncovers human-specific features of brain development","volume":"574","author":"Kanton","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.05.032_bib236","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1038\/s41388-025-03637-0","article-title":"Beyond genomics: 3D microtumor assays for rapid, clinically relevant functional drug testing","volume":"44","author":"Chan","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2026.05.032_bib237","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41698-021-00168-1","article-title":"Patient-derived organoids as a predictive biomarker for treatment response in cancer patients","volume":"5","author":"Wensink","year":"2021","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.apsb.2026.05.032_bib238","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1538-7445.AM2025-5993","article-title":"Identification of predictive biomarkers of response to ADCs by HTS of highly molecularly characterized panels of patient-derived organoids (PDOs)","volume":"85","author":"Tan","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib239","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ccell.2024.03.004","article-title":"Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer","volume":"42","author":"Yang","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2026.05.032_bib240","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1158\/1538-7445.AM2025-5189","article-title":"Exploring the clinical utility of HER2-targeted antibody\u2013drug conjugate in urothelial carcinoma using patient-derived models","volume":"85","author":"Tang","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib241","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/jmcb\/mjaa036","article-title":"Development of a miniaturized 3D organoid culture platform for ultra-high-throughput screening","volume":"12","author":"Du","year":"2020","journal-title":"J Mol Cell Biol"},{"key":"10.1016\/j.apsb.2026.05.032_bib242","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s43018-022-00359-0","article-title":"Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR \u00d7 LGR5 bispecific antibody with efficacy in epithelial tumors","volume":"3","author":"Herpers","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.apsb.2026.05.032_bib243","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1158\/1538-7445.AM2025-5497","article-title":"Sacituzumab govitecan screening in a large organoid panel reveals the importance of functional assays for predicting ADC tumor response","volume":"85","author":"Hornsveld","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.032_bib244","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202513567","article-title":"Tumor microenvironment-responsive nanomedicines for potentiating cancer immunotherapy","volume":"12","author":"Huang","year":"2025","journal-title":"Adv Sci"},{"key":"10.1016\/j.apsb.2026.05.032_bib245","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.addr.2015.12.017","article-title":"The extracellular matrix in breast cancer","volume":"97","author":"Insua-Rodr\u00edguez","year":"2016","journal-title":"Adv Drug Delivery Rev"},{"key":"10.1016\/j.apsb.2026.05.032_bib246","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jconrel.2021.04.024","article-title":"In-vitro tumor microenvironment models containing physical and biological barriers for modelling multidrug resistance mechanisms and multidrug delivery strategies","volume":"334","author":"Rahmanian","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.05.032_bib247","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113584","article-title":"Identification of functional biomarkers for personalized nanomedicine in advanced breast cancer in vitro models","volume":"381","author":"Boix-Montesinos","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.05.032_bib248","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-025-02466-9","article-title":"Exploring personalized prediction of clinical chemotherapy efficacy and revealing tumor heterogeneity using patient-derived 3D bioprinting gastric cancer models","volume":"24","author":"Du","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2026.05.032_bib249","series-title":"NIH establishes nation's first dedicated organoid development center to reduce reliance on animal modeling","year":"2025"},{"key":"10.1016\/j.apsb.2026.05.032_bib250","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70258","article-title":"Vascularised organoids: recent advances and applications in cancer research","volume":"15","author":"Zhou","year":"2025","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.apsb.2026.05.032_bib251","first-page":"45","article-title":"Artificial intelligence virtual organoids (AIVOs)","volume":"59","author":"Bai","year":"2026","journal-title":"Bioact Mater"},{"key":"10.1016\/j.apsb.2026.05.032_bib252","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ccell.2025.03.017","article-title":"Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer","volume":"43","author":"Ma","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2026.05.032_bib253","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj9793","article-title":"Intracellular proteomics and extracellular vesiculomics as a metric of disease recapitulation in 3D-bioprinted aortic valve arrays","volume":"10","author":"Clift","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2026.05.032_bib254","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.drudis.2018.11.014","article-title":"Artificial intelligence in drug development: present status and future prospects","volume":"24","author":"Mak","year":"2019","journal-title":"Drug Discov Today"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526003291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526003291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:16:59Z","timestamp":1789600619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383526003291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":254,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2211383526003291"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2026.05.032","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging organoids and organoids-on-chip platforms for translational development of antibody\u2012drug conjugates and next-generation bioconjugates","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2026.05.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}